<DOC>
	<DOCNO>NCT02464033</DOCNO>
	<brief_summary>The objective study : - Evaluate tolerability combination therapy Diamyd , vitamin D etanercept - Evaluate mention treatment influence immune system endogenous insulin secretion</brief_summary>
	<brief_title>EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial Evaluate Safety Children With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Informed consent give patient parent ( ) /legal guardian ( ) 2 . Type 1 diabetes accord ADA classification , diagnose within previous 100 day time screen 3 . Age 8.00 17.99 year time screen 4 . Fasting Cpeptide time screen ≥0.12 nmol/L 5 . Positive GADA &lt; 50 000 Units 6 . Menarchal female must agree avoid pregnancy negative urine pregnancy test 7 . Immunity Varicella , either previous infection vaccination 8 . Patients must follow Swedish vaccination programme 9 . Patients childbearing potential must agree use adequate contraception , sexually active , 1 year last administration GADalum etanercept . Adequate contraception follow : For female childbearing potential : 1. oral ( except lowdose gestagen ( lynestrenol norestisteron ) , injectable , implanted hormonal contraceptive ( female ) 2. intrauterine device ( female ) 3. intrauterine system ( example , progestinreleasing coil ) ( female ) 4. vasectomize male ( appropriate postvasectomy documentation absence sperm ejaculate ) For male childbearing potential : . Condom ( male ) 1 . Previous current treatment immunosuppressant therapy ( although topical inhale steroid accept ) 2 . Continuous treatment antiinflammatory drug ( sporadic treatment e.g . headache connection fever day accept ) 3 . Treatment oral inject antidiabetic medication ( especially hypoglycemic agent ) insulin 4 . Treatment Vitamin D , market , unwilling abstain medication trial 5 . A history hypercalcemia 6 . A history anaemia significantly abnormal haematology result screen 7 . A history epilepsy , head trauma cerebrovascular accident , clinical feature continuous motor unit activity proximal muscle 8 . Clinically significant history acute reaction vaccine drug past 9 . Treatment vaccine within 4 month prior plan first administration GADAlum plan treatment vaccine 4 month last injection GADAlum , include influenza vaccine 10 . Participation clinical trial new chemical entity within previous 3 month 11 . Inability unwillingness comply provision protocol 12 . A history alcohol drug abuse 13 . A significant illness diabetes within 2 week prior first dose 14 . Known human immunodeficiency virus ( HIV ) 15 . Prior active viral hepatitis B C infection 16 . Females lactate pregnant ( female start menstruate possibility pregnancy must exclude urine βHCG onsite within 24 hour prior GADAlum etanercept administration , respectively ) 17 . Males female willing use adequate contraception , sexually active , 1 year last GADAlum etanercept administration , respectively 18 . Presence associate serious disease condition , include active skin infection preclude subcutaneous injection , opinion investigator make patient noneligible study . 19 . Deemed investigator able follow instruction and/or follow study protocol 20 . Active infection , include chronic local infection history previous tendency serious infection , recent ongoing uncontrolled bacterial , viral , fungal opportunistic infection , know infection active EBV CMV 21 . Hypersensivity active substance Enbrel ( etanercept ) ingredient Enbrel 22 . Active inactive ( latent ) tuberculosis ( TBC ) screen 23 . History malignancy significant cardiovascular disease 24 . Current history leukopenia , anemia and/or thrombocytopeni 25 . Liver disease ( clinical hepatic enzyme &gt; 3 time upper limit normal ( ULN ) ) 26 . Renal insufficiency ( clinical creatinine &gt; 3 time upper limit normal ( ULN ) ) 27 . MS , undefined neurologic condition know SLE , antinuclear know doublestranded DNA antibody positivity 28 . Arrhythmia 29 . Pancreatitis 30 . Vitamin D serum level &gt; 100 nmol/L screen</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diamyd</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Diabetes Type 1</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Insulin Dependent Diabetes</keyword>
	<keyword>Type 1 Diabetes MellitusType 1 Diabetes Mellitus</keyword>
	<keyword>rhGAD65</keyword>
	<keyword>GAD65</keyword>
	<keyword>GAD-Alum</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes mellitus Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Etanercept</keyword>
</DOC>